NCT06787144View on ClinicalTrials.gov

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
CML (Chronic Myelogenous Leukemia)Chronic Phase CML
Interventions
DRUG

ELVN-001

Orally once or twice daily

Trial Locations (4)

Unknown

RECRUITING

Akita University Hospital, Akita

RECRUITING

Aiiku Hospital, Sapporo

RECRUITING

The University of Osaka Hospital, Suita-shi

RECRUITING

Tokyo Medical University Hospital, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Enliven Therapeutics

INDUSTRY

NCT06787144 - ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants | Biotech Hunter | Biotech Hunter